The rapid evolution of biologics and blockbuster obesity therapies is creating an unprecedented demand on the injectable drug delivery market. As these treatments mature and reach millions of patients, the pharmaceutical industry is being forced to rethink dose volumes, supply chain sustainability, and device design.

In this episode of Life Science Solutions, host Chris Adkins sits down with Paul Jansen, a recognized industry voice and veteran leader in medical device development and combination products. Drawing from his extensive background, including leadership roles at Sanofi, Paul explains how the massive success of GLP-1 therapies is shaking up the industry and forcing innovators to adapt.

Topics Include:

• The GLP-1 Ripple Effect: Why the current model of one injection per device is environmentally and economically unsustainable for mass markets, driving the shift toward fixed-dose pens and the future of auto-indexing needles.
• The Rise of Dual Chamber Systems: How the expiration of key patents is opening the door for dual chamber cartridges, allowing for easier lyophilization reconstitution and the sequential delivery of complex, mixed therapies.
• Wearable Injectors: Why on-body wearables haven't hit their predicted "hockey stick" growth yet, and why the industry needs to focus on creating affordable, less-featured baseline devices rather than over-engineering them.
• The Reality of Connected Devices: Why smart connectivity provides massive value for highly motivated patients (such as those undergoing fertility or oncology treatments), but still lacks a clear value proposition for broader populations.
• Platform Innovation: The critical need for device companies to build adaptable technology platforms, collaborate closely with pharma, and integrate patient-centric usability engineering right from the start.

Stay up to date on industry trends as this conversation offers a clear roadmap for the future of combination products.

🎧 Subscribe to Life Science Solutions wherever you get your podcasts, and share this episode with your formulation, quality, and device engineering teams!